
Despite landmark heart failure (HF) with reduced ejection fraction (HFrEF) trials showing effect of Mineralocorticoid Receptor Antagonists (MRA) on the risk of death and HF hospitalization, it has been suggested that MRAs are underutilized or frequently withdrawn. This study sought to identify temporal trends in the initiation of MRAs and the subsequent risk of withdrawal and adherence of MRAs in HF patients treated with a renin‐angiotensin system inhibitor and a beta‐blocker in Denmark from 2003–2017. From nationwide registries, we identified patients receiving a diagnosis of HF. Use of MRA was identified by at least one prescription within six months after the diagnosis...
Like
Save
Share